Biosimilars Market Worth US$ 9.5 Billion by 2022

New York, April 25: Market Research Engine has published a new report titled as “Biosimilars Market By Product Analysis (Recombinant Nonglycosylated Proteins, Recombinant Peptides, Recombinant Glycosylated Proteins); By Application Analysis (Oncology, Blood Disorders, Growth Hormone Deficiency, Chronic and Autoimmune Diseases, Infectious Diseases) and By Regional Analysis – Global Forecast by 2016 - 2022”

How Big is the Global Biosimilars Market?

The Global Biosimilars Market is expected to exceed more than US$ 9.5 billion by 2022 and will grow at a CAGR of more than 26% in the given forecast period.

Browse the full report here: https://www.marketresearchengine.com/biosimilars-market-report

Biosimilar pills include erythropoietin, interferon, insulin, monoclonal antibodies (MABS), granulocyte colony stimulating elements and others. But, vaccines, plasma derived merchandise and their recombinant variations are excluded from the scope of this record. Furthermore, biologic capsules along with streptokinase and hyaluronidase are excluded from the observe due to the absence of right biosimilars recommendations. Patent expiry for reference biologics is placing the pace for the growth of biosimilars in this rather aggressive market. Recreating the patented protein structure for biosimilars is a key venture for regulators, as no two merchandise may be exactly the identical, which in addition complicates the regulatory procedure. Global biopharmaceutical regulators face numerous troubles bearing on the approval of biosimilars for numerous merchandise, because the regulations drafted for every product is precise to their method structure.


The major driving factors of Global Biosimilars Market are as follows:

• Increasing force to curtail healthcare expenditure
• Increasing incidences of diseases
• Rising demand for biosimilars drug due to itscost effectiveness
• Increase in aging population
• Growing government support and initiative to expand and support biosimilars

The restraining factors of Global Biosimilars Market are as follows:

• High manufacturing complexity and expenditure
• Inventive strategies by biologic drug manufacturer

The Global Biosimilars Market is segmented on the lines of its product, application and regional. Based on product segmentation it covers recombinant nonglycosylated proteins, recombinant peptides and recombinant glycosylated proteins. Under application segmentation it covers oncology, blood disorders, growth hormone deficiency, chronic and sutoimmune diseases and infectious diseases. The Global biosimilars Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.


This report provides:

1) An overview of the global market for Biosimilars and related technologies.

2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2022.

3) Identifications of new market opportunities and targeted promotional plans for Global Biosimilars Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.


REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets for Global Biosimilars Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India), Mylan, Inc.(U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and Merck KGaA (Germany). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.

The Global Biosimilars Market has been segmented as below:

By Product Analysis

• Recombinant Nonglycosylated Proteins
• Recombinant Peptides
• Recombinant Glycosylated Proteins

By Application Analysis

• Oncology
• Blood Disorders
• Growth Hormone Deficiency
• Chronic and Autoimmune Diseases
• Infectious Diseases

By Regional Analysis

• North America
• Europe
• Asia-Pacific
• Rest of the World

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Biosimilars Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Biosimilars Market data.
4) Assess your competitor’s refining portfolio and its evolution.

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging healthcare technologies, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862, +91-860-565-7204
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.